Access the full text.
Sign up today, get DeepDyve free for 14 days.
B. Arun, S. Bayraktar, Diane Liu, A. Barrera, D. Atchley, L. Pusztai, J. Litton, V. Valero, F. Meric-Bernstam, G. Hortobagyi, C. Albarracin (2011)
Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 28
R. Scully, Junjie Chen, A. Plug, Yonghong Xiao, D. Weaver, J. Feunteun, T. Ashley, D. Livingston (1997)
Association of BRCA1 with Rad51 in Mitotic and Meiotic CellsCell, 88
DJ Slamon, B Leyland-Jones, S Shak, H Fuchs, V Paton, A Bajamonde (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med, 344
M. Pegram, A. Lipton, D. Hayes, B. Weber, J. Baselga, D. Tripathy, Debbie Baly, S. Baughman, T. Twaddell, J. Glaspy, D. Slamon (1998)
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 8
R. Pietras, M. Pegram, R. Finn, Daniel Maneval, D. Slamon (1998)
Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugsOncogene, 17
P. Tassone, P. Tassone, P. Tagliaferri, A. Perricelli, S. Blotta, B. Quaresima, Marialuisa Martelli, A. Goel, V. Barbieri, F. Costanzo, C. Boland, S. Venuta (2003)
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cellsBritish Journal of Cancer, 88
M. Kriege, C. Seynaeve, H. Meijers-Heijboer, J. Collée, M. Menke-Pluymers, C. Bartels, M. Tilanus-Linthorst, J. Blom, E. Huijskens, A. Jager, A. Ouweland, B. Geel, M. Hooning, C. Brekelmans, J. Klijn (2009)
Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 23
G. Frasci, P. Comella, M. Rinaldo, G. Iodice, M. Bonito, M. D'aiuto, A. Petrillo, S. Lastoria, C. Siani, G. Comella, G. D'aiuto (2009)
Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 20 7
M. Moynahan, Joanne Chiu, B. Koller, M. Jasin (1999)
Brca1 controls homology-directed DNA repair.Molecular cell, 4 4
Ian Collins, Prudence Francis, Linda Mileshkin (2012)
Adjuvant trastuzumab in HER2-positive breast cancer.The New England journal of medicine, 366 7
J. Reis-Filho, L. Pusztai (2011)
Gene expression profiling in breast cancer: classification, prognostication, and predictionThe Lancet, 378
T. Byrski, J. Gronwald, T. Huzarski, E. Grzybowska, M. Budryk, M. Stawicka, T. Mierzwa, M. Szwiec, R. Wiśniowski, M. Siołek, S. Narod, J. Lubiński, The Consortium (2008)
Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancersBreast Cancer Research and Treatment, 108
(2013)
randomized Phase II Study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer
Freddie Hamdy, Jenny Donovan, Athene, Chris Metcalfe, M. Davis, R. Martin, Bollina J., Andrew Doble, Alan Doherty, Gillatt, Gnanapragasam David, O. Hughes, Howard, A. Paul, E. Paez, P. Powell, M. Mason, J. Oxley, J. Lane, M. Davis, E. Turner, G. Young, E. Walsh, R. Bryant, P. Bollina, D. Gillatt, V. Gnanapragasam, O. Hughes, R. Kockelbergh, H. Kynaston, E. Paez, P. Powell, D. Rosario, E. Rowe, M. Mason, T. Peters, J. Oxley, N. Williams, J. Staffurth, D. Neal (2023)
The n e w e n g l a n d j o u r n a l of m e d i c i n e
M. Pegram, T. Pieńkowski, D. Northfelt, W. Eiermann, Ravi Patel, P. Fumoleau, E. Quan, J. Crown, D. Toppmeyer, M. Smylie, A. Riva, S. Blitz, M. Press, D. Reese, M. Lindsay, D. Slamon (2004)
Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.Journal of the National Cancer Institute, 96 10
J. Thigpen (2011)
Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast CancerYearbook of Medicine, 2011
B. Evers, R. Drost, Eva Schut, M. Bruin, Eline Burg, P. Derksen, H. Holstege, Xiaoling Liu, E. Drunen, H. Beverloo, G. Smith, N. Martin, A. Lau, M. O’Connor, J. Jonkers (2008)
Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and CisplatinClinical Cancer Research, 14
C. Clark, J. Weitzel, T. O'Connor (2012)
Enhancement of Synthetic Lethality via Combinations of ABT-888, a PARP Inhibitor, and Carboplatin In Vitro and In Vivo Using BRCA1 and BRCA2 Isogenic ModelsMolecular Cancer Therapeutics, 11
E. Perez, V. Suman, K. Rowland, J. Ingle, M. Salim, C. Loprinzi, P. Flynn, J. Mailliard, C. Kardinal, J. Krook, Abby Thrower, D. Visscher, R. Jenkins (2005)
Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.Clinical breast cancer, 6 5
A. González-Angulo, K. Timms, Shuying Liu, Huiqin Chen, J. Litton, J. Potter, J. Lanchbury, K. Stemke‐Hale, B. Hennessy, B. Arun, G. Hortobagyi, K. Do, G. Mills, F. Meric-Bernstam (2011)
Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast CancerClinical Cancer Research, 17
J. Balmaña, N. Tung, S. Isakoff, B. Graña, P. Ryan, R. Rafi, M. Tracy, E. Winer, J. Baselga, J. Garber (2012)
Phase I, open-label study of olaparib plus cisplatin in patients with advanced solid tumors.Journal of Clinical Oncology, 30
A. Bhattacharyya, Uy Ear, B. Koller, R. Weichselbaum, D. Bishop (2000)
The Breast Cancer Susceptibility Gene BRCA1 Is Required for Subnuclear Assembly of Rad51 and Survival following Treatment with the DNA Cross-linking Agent Cisplatin*The Journal of Biological Chemistry, 275
Paula Ryan, N. Tung, S. Isakoff, Mehra Golshan, Andrea Richardson, A. Corben, Barbara Smith, R. Gelman, E. Winer, Judy Garber (2016)
Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 15_suppl
G. Somlo, J. Sparano, T. Cigler, G. Fleming, T. Luu, A. Hurria, J. Mortimer, P. Frankel, H. Chew, R. Nanda, Cynthia Ma, A. Chen, Agustin Garcia, L. Vahdat, D. Gandara, J. Weitzel (2012)
ABT-888 (veliparib) in combination with carboplatin in patients with stage IV BRCA-associated breast cancer. A California Cancer Consortium Trial.Journal of Clinical Oncology, 30
J. Baselga (2010)
Treatment of HER2-overexpressing breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 21 Suppl 7
S. Delaloge, F. Bidard, Y. Masmoudi, B. Paillerets, O. Caron, C. Bourgier, J. Garbay, M. Spielmann, F. André (2008)
BRCA1 germ-line mutation: Predictive of sensitivity to anthracyclin alkylating agents regimens but not to taxanes?Journal of Clinical Oncology, 26
(2007)
Cisplatin and its analogues in the treatment of advanced breast cancer : a review
H. Bryant, N. Schultz, H. Thomas, Kayan Parker, Dan Flower, Elena Lopez, S. Kyle, M. Meuth, N. Curtin, T. Helleday (2007)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseNature, 447
Y. Drew, E. Mulligan, Wan-Tse Vong, H. Thomas, Samra Kahn, S. Kyle, A. Mukhopadhyay, G. Los, Z. Hostomský, E. Plummer, R. Edmondson, N. Curtin (2011)
Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.Journal of the National Cancer Institute, 103 4
Z. Siddik (2003)
Cisplatin: mode of cytotoxic action and molecular basis of resistanceOncogene, 22
O. Metzger-Filho, A. Tutt, E. Azambuja, K. Saini, G. Viale, S. Loi, I. Bradbury, J. Bliss, H. Azim, P. Ellis, A. Leo, J. Baselga, C. Sotiriou, M. Piccart-Gebhart (2012)
Dissecting the heterogeneity of triple-negative breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 15
A. Prat, C. Perou (2010)
Deconstructing the molecular portraits of breast cancerMolecular Oncology, 5
T. Byrski, R. Dent, P. Blecharz, M. Foszczyńska‐Kłoda, J. Gronwald, T. Huzarski, C. Cybulski, E. Marczyk, R. Chrzan, A. Eisen, J. Lubiński, S. Narod (2012)
Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancerBreast Cancer Research : BCR, 14
A. Husain, G. He, E. Venkatraman, D. Spriggs (1998)
BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II).Cancer research, 58 6
A. Jemal, F. Bray, Melissa Center, J. Ferlay, Elizabeth Ward, David Forman (2011)
Global Cancer Statistics
V. Valero, J. Forbes, M. Pegram, T. Pieńkowski, W. Eiermann, G. Minckwitz, H. Roché, Miguel Martín, J. Crown, J. Mackey, P. Fumoleau, J. Rolski, Z. Mršić-Krmpotić, A. Jagiełło-Gruszfeld, A. Riva, M. Buyse, H. Taupin, G. Sauter, M. Press, D. Slamon (2011)
Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 2
T. Byrski, J. Gronwald, T. Huzarski, R. Dent, D. Zuziak, R. Wiśniowski, E. Marczyk, P. Blecharz, O. Szurek, C. Cybulski, T. Dębniak, B. Górski, J. Lubiński, S. Narod (2011)
Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patientsHereditary Cancer in Clinical Practice, 9
H. Yap, P. Salem, G. Hortobagyi, G. Bodey, A. Buzdar, C. Tashima, G. Blumenschein (1978)
Phase II study of cis-dichlorodiammineplatinum(II) in advanced breast cancer.Cancer treatment reports, 62 3
(2012)
Phase I, open-label study of olaparib plus cisplatin in patients with Curr Breast Cancer Rep (2013) 5:11–22 21 advanced solid tumors
R. Drost, P. Bouwman, S. Rottenberg, U. Boon, Eva Schut, S. Klarenbeek, C. Klijn, Ingrid Heijden, H. Gulden, E. Wientjens, Mark Pieterse, A. Catteau, Peter Green, E. Solomon, Joanna Morris, J. Jonkers (2011)
BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.Cancer cell, 20 6
N. Robert, B. Leyland-Jones, L. Asmar, R. Belt, D. Ilegbodu, D. Loesch, R. Raju, Elizabeth Valentine, R. Sayre, M. Cobleigh, K. Albain, Cecelia McCullough, L. Fuchs, D. Slamon (2006)
Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18
T. Sørlie, R. Tibshirani, Joel Parker, T. Hastie, J. Marron, A. Nobel, Shibing Deng, H. Johnsen, Robert Pesich, S. Geisler, J. Demeter, C. Perou, P. Lønning, P. Brown, A. Børresen-Dale, D. Botstein (2003)
Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences of the United States of America, 100
M. Higgins, J. Baselga (2011)
Targeted therapies for breast cancer.The Journal of clinical investigation, 121 10
S. Vukelja, J. O’Shaughnessy, D. Weckstein (2007)
Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer
S. Isakoff, P. Goss, E. Mayer, T. Traina, L. Carey, K. Krag, H. Rugo, M. Liu, V. Stearns, S. Come, D. Borger, C. Quadrino, D. Finkelstein, J. Garber, P. Ryan, E. Winer, L. Ellisen (2011)
TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 15_suppl
G. Frasci, G. D'aiuto, P. Comella, R. Thomas, G. Iodice, G. Botti, M. Bonito, M. D'aiuto, M. Rubulotta, G. Comella (2008)
Weekly cisplatin-epirubicin-paclitaxel with G-CSF support in ER-negative large operable breast cancer. The NCI of Naples’ nine-year experienceJournal of Clinical Oncology, 26
S. Rottenberg, J. Jaspers, A. Kersbergen, Eline Burg, A. Nygren, Serge Zander, P. Derksen, M. Bruin, J. Zevenhoven, A. Lau, R. Boulter, A. Cranston, M. O’Connor, N. Martin, P. Borst, J. Jonkers (2008)
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugsProceedings of the National Academy of Sciences, 105
D. Parkin (2001)
Global cancer statistics in the year 2000.The Lancet. Oncology, 2 9
L. Carey, H. Rugo, P. Marcom, E. Mayer, F. Esteva, Cynthia Ma, Minetta Liu, A. Storniolo, M. Rimawi, A. Forero-Torres, A. Wolff, T. Hobday, A. Ivanova, W. Chiu, M. Ferraro, E. Burrows, P. Bernard, K. Hoadley, C. Perou, Eric Winer (2012)
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 21
A. Miranda, F. Medina, C. Arce, N. Castañeda-Soto, C. Blanco, J. Ponce, E. Rocha, V. Pérez-Sánchez (2011)
Phase II open, single-arm trial: Cisplatin combined with paclitaxel and doxorubicin in operable or locally advanced triple-negative breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 15_suppl
L. Kelland (2007)
The resurgence of platinum-based cancer chemotherapyNature Reviews Cancer, 7
(2006)
Randomized phase III study of trastuzumab , paclitaxel , and carboplatin compared with trastuzumab and paclitaxel in women with HER - 2 - overexpressing metastatic breast can
H. Farmer, N. Mccabe, C. Lord, A. Tutt, Damian Johnson, T. Richardson, M. Santarosa, Krystyna Dillon, I. Hickson, C. Knights, N. Martin, S. Jackson, G. Smith, A. Ashworth (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 434
T. Byrski, J. Gronwald, T. Huzarski, E. Grzybowska, M. Budryk, M. Stawicka, T. Mierzwa, M. Szwiec, R. Wiśniowski, M. Siołek, R. Dent, J. Lubiński, S. Narod (2010)
Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 3
D. Silver, A. Richardson, A. Eklund, Z. Wang, Z. Szallasi, Qiyuan Li, N. Juul, C. Leong, Diana Calogrias, Ayodele Buraimoh, Aquila Fatima, R. Gelman, P. Ryan, N. Tung, A. Nicolo, S. Ganesan, A. Miron, C. Colín, D. Sgroi, L. Ellisen, E. Winer, J. Garber (2010)
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 7
T. Byrski, T. Huzarski, R. Dent, J. Gronwald, D. Zuziak, C. Cybulski, J. Kładny, B. Górski, J. Lubiński, S. Narod (2009)
Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patientsBreast Cancer Research and Treatment, 115
R. Pietras, B. Fendly, V. Chazin, M. Pegram, S. Howell, D. Slamon (1994)
Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.Oncogene, 9 7
P. Chappuis, J. Goffin, N. Wong, C. Perret, P. Ghadirian, P. Tonin, W. Foulkes (2002)
A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancerJournal of Medical Genetics, 39
E. Rakha, J. Reis-Filho, I. Ellis (2008)
Basal-like breast cancer: a critical review.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 15
M. Pegram, Sheree Hsu, G. Lewis, R. Pietras, Malgorzata Beryt, M. Sliwkowski, D. Coombs, D. Baly, F. Kabbinavar, D. Slamon (1999)
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancersOncogene, 18
J. O’Shaughnessy, L. Schwartzberg, M. Danso, H. Rugo, K. Miller, D. Yardley, Robert Carlson, R. Finn, Eric Charpentier, M. Freese, Sanjay Gupta, A. Blackwood-Chirchir, Eric Winer (2011)
A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 15_suppl
N. Turner, A. Tutt, A. Ashworth (2004)
Hallmarks of 'BRCAness' in sporadic cancersNature Reviews Cancer, 4
J O’Shaughnessy, C Osborne, JE Pippen, M Yoffe, D Patt, C Rocha (2011)
Iniparib plus chemotherapy in metastatic triple-negative breast cancerN Engl J Med, 364
P. Kern, H. Kolberg, A. Kalisch, C. Liedtke, F. Otterbach, R. Kimmig, C. Kurbacher (2011)
Pathologic response rate (pCR) and near-pathologic response rate (near-pCR) with docetaxel-carboplatin (TCarb) in early triple-negative breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 27_suppl
J. Thigpen (2011)
Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic RegimensYearbook of Medicine, 2011
(2011)
TBCRC 009 : A multicenter phase II study of cisplatin or carboplatin for metastatic triple - negative breast cancer and evaluation of p 63 / p 73 as a biomarker of response
E. Rodler, J. Specht, V. Gadi, B. Kurland, M. Griffin, J. Hammond, J. Gralow (2011)
P1-17-04: Phase I Study of PARP Inhibitor ABT-888 (Veliparib) in Combination with Cisplatin and Vinorelbine for Patients with Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer.Cancer Research, 71
Platinum compounds have recently resurged as promising old agents for treatment of breast cancer in some specific subgroups of patients. The recognition of breast cancer as a heterogeneous disease with a genomic classification of at least 4 subtypes, the fact that platinum compounds could synergistically enhance anti-HER2 efficacy in the HER2 positive breast cancer, and the observation that platinum derivates were highly active in tumors with homologous recombination deficiency, such as BRCA-associated or basal-like breast cancer, have raised the interest in cisplatin and carboplatin. This review will focus on the recent data published regarding the use of these agents in monotherapy or in combination, and will shed some light on the challenges currently facing the use of these compounds in the standard care of our breast cancer patients.
Current Breast Cancer Reports – Springer Journals
Published: Jan 6, 2013
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.